MediciNova and Avigen Move One Step Closer To A Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Two months after unveiling a tentative framework for a merger, MediciNova and Avigen hammer out an agreement that gives MediciNova ownership of Avigen's remaining assets for a song.
You may also be interested in...
Avigen’s Argument With Largest Shareholder Emblematic Of Biotech Troubles
Biotechnology Value Fund wants the firm to accept a merger offer from MediciNova; Avigen wants more time to keep rolling the dice.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.